USA

Moderna’s (MRNA) stock has more fuel in the tank, says analyst

Accordingly, Carr rates Moderna a purchase along with a target price of $ 94. Investors could be pocketing a profit of 17%, should the analyst’s thesis develop during next year. (To see Carr’s history, Click here) Overall, the Needham analyst gets strong support from the rest of the analyst community. …

Read More »